Cargando…
Thymostimulin versus placebo for palliative treatment of locally advanced or metastasised hepatocellular carcinoma: a phase III clinical trial
BACKGROUND: Thymostimulin is a thymic peptide fraction with immune-mediated cytotoxicity against hepatocellular carcinoma (HCC) in vitro and palliative efficacy in advanced HCC in two independent phase II trials. The aim of this study was to assess the efficacy of thymostimulin in a phase III trial....
Autores principales: | Dollinger, Matthias M, Lautenschlaeger, Christine, Lesske, Joachim, Tannapfel, Andrea, Wagner, Anna-Dorothea, Schoppmeyer, Konrad, Nehls, Oliver, Welker, Martin-Walter, Wiest, Reiner, Fleig, Wolfgang E |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2936330/ https://www.ncbi.nlm.nih.gov/pubmed/20735834 http://dx.doi.org/10.1186/1471-2407-10-457 |
Ejemplares similares
-
Thymostimulin in advanced hepatocellular carcinoma: A phase II trial
por: Dollinger, Matthias M, et al.
Publicado: (2008) -
Discriminating metastasised from non-metastasised seminoma based on transcriptional changes in primary tumours using NGS
por: Ruf, C G, et al.
Publicado: (2014) -
Breast cancer metastasising to the uterine cervix.
por: Bryson, C. A., et al.
Publicado: (1999) -
Feline paraneoplastic alopecia associated with metastasising intestinal carcinoma
por: Grandt, Lisa-Maria, et al.
Publicado: (2015) -
Supportive mistletoe therapy in a patient with metastasised neuroblastoma
por: Kaestner, Jens, et al.
Publicado: (2019)